Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.

See more here:
FDA grants Fast Track designation to Juventas’ JVS-100 drug candidate and allows Phase 2b clinical trial

Scroll to Top